Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson for severe traumatic haemorrhagic shock
ISRCTN44262421Phase 2Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of regadenoson in hemorrhagic shock and Physical trauma (5 arms), sponsored by Queen Mary University of London. Primary endpoint: Lactate at 2 hours post investigational product administration. Started Aug 2020; status: recruiting.
02
Drugs
regadenoson
03
Conditions
hemorrhagic shockPhysical trauma
Beyond the preview
Go deeper on ISRCTN44262421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44262421.